354 related articles for article (PubMed ID: 25144265)
41. Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy.
Feinberg B; Gilmore J; Haislip S; Jackson J; Jain G; Balu S; Buchner D
Support Care Cancer; 2012 Mar; 20(3):615-23. PubMed ID: 21761096
[TBL] [Abstract][Full Text] [Related]
42. Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study.
Celio L; Cortinovis D; Cogoni AA; Cavanna L; Martelli O; Carnio S; Collovà E; Bertolini F; Petrelli F; Cassano A; Chiari R; Zanelli F; Pisconti S; Vittimberga I; Letizia A; Misino A; Gernone A; Bonizzoni E; Pilotto S; De Placido S; Bria E
Oncologist; 2021 Oct; 26(10):e1854-e1861. PubMed ID: 34101934
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of fosaprepitant combined with tropisetron plus dexamethasone in preventing nausea and emesis during fractionated radiotherapy with weekly cisplatin chemotherapy: interim analysis of a randomized, prospective, clinical trial using competing risk analysis.
Xie S; Huang R; Zhan Y; Cai Q; Wu Y; Huang K; Lin X; Wang R; Yan Y; Xie R; Wang S; Zeng C; Chen C
Support Care Cancer; 2023 Oct; 31(12):640. PubMed ID: 37851143
[TBL] [Abstract][Full Text] [Related]
44. A modified olanzapine-based anti-emetic regimen for the control of nausea and vomiting in patients receiving weekly cisplatin.
Mehra N; Christopher V; Dhanushkodi M; Radhakrishnan V; Ganesan TS; Ganesharajah S; Sagar TG; Ganesan P
Int J Clin Pharm; 2020 Apr; 42(2):662-666. PubMed ID: 32152887
[TBL] [Abstract][Full Text] [Related]
45. Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy.
Hamada S; Hinotsu S; Kawai K; Yamada S; Narita S; Kamba T; Nishiyama H; Arai Y; Habuchi T; Ogawa O; Kawakami K
Support Care Cancer; 2014 Aug; 22(8):2161-6. PubMed ID: 24652048
[TBL] [Abstract][Full Text] [Related]
46. Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen.
Hesketh PJ; Roman A; Hesketh AM; Perez EA; Edelman M; Gandara DR
Support Care Cancer; 2000 Jan; 8(1):46-8. PubMed ID: 10650897
[TBL] [Abstract][Full Text] [Related]
47. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
48. Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: A pilot study.
Deauna-Limayo D; Aljitawi OS; Ganguly S; Abhyankar S; Wick JA; McGuirk JP
J Oncol Pharm Pract; 2014 Aug; 20(4):263-9. PubMed ID: 24005093
[TBL] [Abstract][Full Text] [Related]
49. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Hashimoto H; Abe M; Tokuyama O; Mizutani H; Uchitomi Y; Yamaguchi T; Hoshina Y; Sakata Y; Takahashi TY; Nakashima K; Nakao M; Takei D; Zenda S; Mizukami K; Iwasa S; Sakurai M; Yamamoto N; Ohe Y
Lancet Oncol; 2020 Feb; 21(2):242-249. PubMed ID: 31838011
[TBL] [Abstract][Full Text] [Related]
50. Comparison of ondansetron with metoclopramide in prevention of acute emesis associated with low dose & high dose cisplatin chemotherapy.
Bhatia A; Tripathi KD; Sharma M
Indian J Med Res; 2003 Jul; 118():33-41. PubMed ID: 14748464
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and Safety of Oral NEPA (Netupitant/Palonosetron), the First Fixed-Combination Antiemetic, in Patients With Gynecological Cancers Receiving Platinum-Based Chemotherapy.
Bošnjak SM; Stamatovic L; Borroni ME; Rizzi G; Jordan K
Int J Gynecol Cancer; 2018 Jul; 28(6):1153-1161. PubMed ID: 29794499
[TBL] [Abstract][Full Text] [Related]
52. Antiemetic therapy of fosaprepitant, palonosetron, and dexamethasone combined with cisplatin-based chemotherapy for head and neck carcinomas.
Tsukahara K; Nakamura K; Motohashi R; Sato H; Endo M; Katsube Y; Ueda Y; Suzuki M
Acta Otolaryngol; 2014 Nov; 134(11):1198-204. PubMed ID: 25315920
[TBL] [Abstract][Full Text] [Related]
53. Daily low-dose cisplatin-based concurrent chemoradiotherapy in patients with uterine cervical cancer with emphasis on elderly patients: a phase 2 trial.
Mitsuhashi A; Uno T; Usui H; Nishikimi K; Yamamoto N; Watanabe M; Tate S; Hirashiki K; Kato K; Yamazawa K; Shozu M
Int J Gynecol Cancer; 2013 Oct; 23(8):1453-8. PubMed ID: 23266648
[TBL] [Abstract][Full Text] [Related]
54. Palonosetron Prevents Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Oral Cancer Patients.
Sento S; Kitamura N; Yamamoto T; Nakashiro K; Hamakawa H; Ibaragi S; Sasaki A; Takamaru N; Miyamoto Y; Kodani I; Ryoke K; Mishima K; Ueyama Y;
Anticancer Res; 2017 Dec; 37(12):6977-6981. PubMed ID: 29187483
[TBL] [Abstract][Full Text] [Related]
55. Low-dose dexamethasone with fosaprepitant and palonosetron to prevent cisplatin-induced nausea and vomiting in head and neck cancer patients.
Kono T; Ueda T; Takumida M; Furuie H; Hamamoto T; Takeno S; Hirakawa K
Acta Otolaryngol; 2018 Oct; 138(10):921-925. PubMed ID: 30016902
[TBL] [Abstract][Full Text] [Related]
56. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V
J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
[TBL] [Abstract][Full Text] [Related]
57. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.
Kris MG; Pendergrass KB; Navari RM; Grote TH; Nelson AM; Thomas V; Ferguson BB; Allman DS; Pizzo BA; Baker TW; Fernando IJ; Chernoff SB
J Clin Oncol; 1997 May; 15(5):2135-8. PubMed ID: 9164228
[TBL] [Abstract][Full Text] [Related]
58. Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: A phase II study.
Isoda A; Saito R; Komatsu F; Negishi Y; Oosawa N; Ishikawa T; Miyazawa Y; Matsumoto M; Sawamura M; Manaka A
Int J Hematol; 2017 Apr; 105(4):478-484. PubMed ID: 27873176
[TBL] [Abstract][Full Text] [Related]
59. [Comparison of the effect of palonosetron versus tropisetron in prevention of vomiting in patients receiving high dose cisplatin-based chemotherapy].
Li RC; Zheng LJ; Qiu H
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):228-31. PubMed ID: 22780980
[TBL] [Abstract][Full Text] [Related]
60. Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone.
Hesketh PJ; Gandara DR; Hesketh AM; Edelman M; Webber LM; McManus M; Hainsworth JD
Cancer J Sci Am; 1997; 3(3):180-3. PubMed ID: 9161784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
